ES2113106T3 - Esteres de 14alfa,15alfa-metilen-estradiol con efecto estrogeno administrables por via oral. - Google Patents

Esteres de 14alfa,15alfa-metilen-estradiol con efecto estrogeno administrables por via oral.

Info

Publication number
ES2113106T3
ES2113106T3 ES94917548T ES94917548T ES2113106T3 ES 2113106 T3 ES2113106 T3 ES 2113106T3 ES 94917548 T ES94917548 T ES 94917548T ES 94917548 T ES94917548 T ES 94917548T ES 2113106 T3 ES2113106 T3 ES 2113106T3
Authority
ES
Spain
Prior art keywords
methylene
effects
15alfa
14alfa
estres
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES94917548T
Other languages
English (en)
Inventor
Sigfrid Schwarz
Hans-Joachim Siemann
Harry Henkel
Kurt Ponsold
Michael Dittgen
Sabine Fricke
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jenapharm GmbH and Co KG
Original Assignee
Jenapharm GmbH and Co KG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jenapharm GmbH and Co KG filed Critical Jenapharm GmbH and Co KG
Application granted granted Critical
Publication of ES2113106T3 publication Critical patent/ES2113106T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J53/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by condensation with a carbocyclic rings or by formation of an additional ring by means of a direct link between two ring carbon atoms, including carboxyclic rings fused to the cyclopenta(a)hydrophenanthrene skeleton are included in this class
    • C07J53/002—Carbocyclic rings fused
    • C07J53/004—3 membered carbocyclic rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

LA PRESENTE INVENCION SE REFIERE A ESTERES 14 AL , 15 AL METILENO - ESTRADIOL, DONDE LOS GRUPOS 17 - HIDROXI Y/O LOS GRUPOS 3 - HIDROXI SE ESTERIFICAN. ESTOS ESTERES SON ADECUADOS PARA SU UTILIZACION, CONJUNTAMENTE CON PRODUCTOS AUXILIARES FARMACEUTICOS, COMO MEDICAMENTO, EN PARTICULAR COMO AGENTES CONTRACEPTIVOS O ANTICLIMATERICOS. EXHIBEN UNA ACCION ESTROGENICA QUE ES COMPARADA DE FORMA PRECISA DEFINIDA CON LA DEL ESTRADIOL ETINILO O ESTROGENOS NATURALES, Y SE ADMINISTRAN CON PREFERENCIA DE FORMA ORAL. NO SOLAMENTE SON REDUCIDOS LOS EFECTOS ASOCIADOS DEL AGENTE CONTRACEPTIVO HABITUAL, SINO TAMBIEN SE MEJORA DE MANERA SIGNIFICANTE LA TERAPIA DE SUSTITUCION DE ESTROGENO.
ES94917548T 1993-07-03 1994-06-15 Esteres de 14alfa,15alfa-metilen-estradiol con efecto estrogeno administrables por via oral. Expired - Lifetime ES2113106T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE4322186A DE4322186A1 (de) 1993-07-03 1993-07-03 Oral estrogen wirksame Ester des 14alpha, 15alpha-Methylen-estradiols

Publications (1)

Publication Number Publication Date
ES2113106T3 true ES2113106T3 (es) 1998-04-16

Family

ID=6491888

Family Applications (1)

Application Number Title Priority Date Filing Date
ES94917548T Expired - Lifetime ES2113106T3 (es) 1993-07-03 1994-06-15 Esteres de 14alfa,15alfa-metilen-estradiol con efecto estrogeno administrables por via oral.

Country Status (8)

Country Link
EP (1) EP0707593B1 (es)
CN (1) CN1102830A (es)
AT (1) ATE161542T1 (es)
AU (1) AU6923494A (es)
DE (3) DE4322186A1 (es)
ES (1) ES2113106T3 (es)
GR (1) GR3026094T3 (es)
WO (1) WO1995001988A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19906159A1 (de) * 1999-02-09 2000-08-10 Schering Ag 16-Hydroxyestratriene als selektiv wirksame Estrogene

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA745995A (en) * 1962-08-17 1966-11-08 Paturet Michel 3 ou 17-hexahydrobenzyloxycarbonates de composes steroides et procede
DD145919B1 (de) * 1978-06-28 1982-06-30 Kurt Ponsold Verfahren zur herstellung von 14,1 -methylenderivaten der oestranreihe
FR2531089B1 (fr) * 1982-07-27 1986-03-21 Pharmascience Lab Nouveaux derives oestraniques destines a des applications pharmacologiques par voie topique, et leur procede de preparation
DE4239946C2 (de) * 1992-11-27 2001-09-13 Jenapharm Gmbh Estranderivate mit einer 14alpha,15alpha-Methylengruppe und Verfahren zu ihrer Herstellung

Also Published As

Publication number Publication date
DE59404903D1 (de) 1998-02-05
ATE161542T1 (de) 1998-01-15
DE4322186A1 (de) 1995-01-12
WO1995001988A1 (de) 1995-01-19
AU6923494A (en) 1995-02-06
EP0707593A1 (de) 1996-04-24
EP0707593B1 (de) 1997-12-29
CN1102830A (zh) 1995-05-24
DE4494826D2 (de) 1997-07-24
GR3026094T3 (en) 1998-05-29

Similar Documents

Publication Publication Date Title
GEP20033094B (en) Steroid Sulphatase Inhibitors
LU91065I2 (fr) Drospirenone en combinaison avec oestradiol et leurs dérivés pharmaceutiquement acceptables (Allurene-Angeliq)
DK0402950T3 (da) Behandling af postmenopausale ulemper
LU90634I2 (fr) Gestodene et ethinylestradiol/minesse
EP1935423A3 (de) Zusammensetzung zur Behandlung und/oder Prophylaxe von Tumoren der Brustdrüsen
BG104620A (en) Oral pharmaceutical extended release dosage form
CA2069483A1 (en) Steroid sulphatase inhibitors
UA37259C2 (uk) Активна речовина для одержання лікарських засобів при лікуванні дисфункціональних маткових кровотеч
MX9804395A (es) Proceso y equipo anticonceptivos para mamiferos hembra, que comprenden una combinacion de gestageno y estrogeno.
NZ312303A (en) Novel nor-pregnanes for inducing hypothalamic effects
LU90341I2 (fr) 75 Ug de désogestrel en l'absence éthinyl oestradiol (cerazette)
BR9710566A (pt) M-todo anticoncepcional monof sico e um kit compreendendo uma combina-Æo de uma progestina e estrog-nio
BR9912466A (pt) Utilização de sulfamatos de estrogênio biogênicos na terapia de reposição hormonal
BR0114665A (pt) Uso de antiprogestinas para a profilaxia e tratamento de doenças dependentes de hormÈnio
AU2732597A (en) Novel pharmaceutical compositions having steroid nitrate ester derivatives useful as anti-inflammatory drugs
BR9809678A (pt) Derivados de triptolìdeo úteis no tratamento de doenças autoimunes
CA2258177A1 (en) 19-nor-cholane steroids as neurochemical initiators of change in human hypothalamic function
ES2113106T3 (es) Esteres de 14alfa,15alfa-metilen-estradiol con efecto estrogeno administrables por via oral.
GR3025872T3 (en) Orally active derivatives of 1,3,5(10)-estratriene
FI956028A0 (fi) Estreenisteroidit ihmisen hypotalaamisen toiminnan muuttamisen neurokemiallisina initiaattoreina sekä tähän liittyvät farmaseuttiset koostumukset ja menetelmät
Baird Clinical use of mifepristone (RU 486)
HUP0000569A3 (en) Use of equilenin for producing pharmaceutical compositions for the treatment of free radical induced disease states
BG101173A (en) Vaccine against pasteurellosis and haemorrhagic disease in rabbits
MXPA94000705A (es) Esteroides de estreno como iniciadores neuroquimicos del cambio en la funcion hipotalamica humana ycomposiciones farmaceuticas y metodos relacionados.
IT1254688B (it) Composizioni farmaceutiche somministrabili per via orale a rilascio mirato contenenti acido ursodesossicolico ed acido chenodesossicolico.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 707593

Country of ref document: ES